Grant: Engage Grants Program
University of Waterloo
$24,710.00
Novel methodology development and optimization to access alkyl alpha-alpha-difluorosulfonamides
FY 2012-13
Summary
Approximately 20% of all modern pharmaceuticals contain at least one fluorine atom. By introducing fluorine
at strategic locations in molecules chemists are able to modulate drug-target interactions, enhance the ability of
the drug to pass through cell membranes and increase the drug's metabolic stability.
The ability to access novel synthetic chemistries is essential to the development of novel medicines for
medically important and challenging diseases as it enables medicinal chemists to prepare previously
inaccessible molecules which will lead to the discovery of new bioactive molecules. Accessing fluorinated
molecules efficiently and selectively continues to be a challenge which limits medicinal chemist's abilities to
evaluate these compounds for physiochemical properties and biological activities. The focus of this application
is to develop new and improved methodologies for preparing a class of fluorinated compounds called alkyl
alpha,alpha-difluorosulfonamides. This class of compounds has potential as pharmaceuticals, however; they
have not been widely examined as such by the pharmaceutical industry mainly because they have been difficult
to prepare. By developing improved methods for synthesizing these compounds Vertex will be able to create
better research tools for discovering novel therapies as well as methodologies to make small molecules to
probe and modulate biological activities.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
437470-2012
Name nom
Taylor, Scott
Department département
Chemistry
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
24710
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3703
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic syntheses
Research subject fr
Synthèses organiques
Partie
1
Nb partie
1
Application title
Novel methodology development and optimization to access alkyl alpha-alpha-difluorosulfonamides
Keyword
NSERC
Application summary
Approximately 20% of all modern pharmaceuticals contain at least one fluorine atom. By introducing fluorine
at strategic locations in molecules chemists are able to modulate drug-target interactions, enhance the ability of
the drug to pass through cell membranes and increase the drug's metabolic stability.
The ability to access novel synthetic chemistries is essential to the development of novel medicines for
medically important and challenging diseases as it enables medicinal chemists to prepare previously
inaccessible molecules which will lead to the discovery of new bioactive molecules. Accessing fluorinated
molecules efficiently and selectively continues to be a challenge which limits medicinal chemist's abilities to
evaluate these compounds for physiochemical properties and biological activities. The focus of this application
is to develop new and improved methodologies for preparing a class of fluorinated compounds called alkyl
alpha,alpha-difluorosulfonamides. This class of compounds has potential as pharmaceuticals, however; they
have not been widely examined as such by the pharmaceutical industry mainly because they have been difficult
to prepare. By developing improved methods for synthesizing these compounds Vertex will be able to create
better research tools for discovering novel therapies as well as methodologies to make small molecules to
probe and modulate biological activities.